RUNX1-FPD is considered an ultra-rare disease and has received little attention.
Imagine living your life knowing that you or your loved one has a 50% average lifetime risk of getting a blood cancer (actual range 11-100%; median, 44%). There is no treatment for patients with RUNX1-FPD. Yet, studying this disease not only has the potential to help every RUNX1 patient worldwide, but also may inform many more general areas of cancer research, including prevention, early detection and treatment.
We need your help
Although The Babich Family, along with generous help from the Leukemia and Lymphoma Society and Alex’s Lemonade Stand Foundation for Childhood Cancer, fund the RUNX1 Research Program’s basic programs and administration costs, additional funding would mean we can do more to accelerate our research and provide more patient resources.
While we are proud of the over $4.5 million we, along with the generous help from our partners, have funded in research grants, the more money we can raise to expand our research efforts and to build patient and clinician education programs the faster we can get to a cure. 100% of your donation will go towards these initiatives, with administrative costs covered by the RUNX1 Research Program.
Checks should be made out to the RUNX1 Research Program and addressed to:
The RUNX1 Research Program
1482 E Valley Rd, Ste 137
Santa Barbara, CA 93108
The RUNX1 Research Program is a 501(c)(3) organization, and all monetary donations are tax deductible to the fullest extent allowed by tax laws. Check with your financial advisor if you have more questions.
Breaking New Ground
The NIH has just initiated the first-ever longitudinal natural history study of RUNX1-FPD patients, with the aim of better understanding the clinical features of the disease, how these may relate to the different germline mutations and why some patients progress to blood cancer and others do not. This is a groundbreaking study and essential in our effort to find a cure.